Luciana Preger, VP and Head, Oncology, Global Medical Affairs at Gilead Sciences, shared on LinkedIn:
“Thank you Good Morning America , for helping raise awareness of metastatic triple-negative breast cancer (mTNBC) and the innovative treatment options bringing new hope to patients.
It was a privilege to meet Janet, who is living with mTNBC. Hearing about her experience and treatment with an antibody-drug conjugate (ADC) was incredibly inspiring.
During our conversation, we discussed how novel therapies are creating possibilities for people facing one of the most aggressive forms of breast cancer.
To advance oncology, we must elevate patient voices, address real-world challenges, and continue pushing the boundaries of innovation.
Thank you, Janet, for sharing your story, your time, and your family with us. Your strength, resilience, and optimism reflect the purpose that drives us at Gilead Sciences every day.
Watch our full conversation here.”
You can also read: Breast Cancer Treatment Sequencing 2026: Powerful New Insights for Better Outcomes
